Wednesday, January 05, 2022
Filament Health (FLHLF)
New Phase 2 Trial for PEX010 Approved To Begin In 1Q22
Filament Health Corp is a natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer’s License.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Additional Phase 2 Study Announced. Filament announced that Health Canada approved a new Phase 2 clinical trial to test PEX010 in persistent depressive disorder (PDD). The trial will test a 1 milligram microdose of PEX010 against placebo to determine safety and efficacy of the microdosing.
Study Design Uses A Lower Dose. The Phase 2 trial will test a 1 mg dose of PEX-010, Filament’s botanically derived psilocybin. It is designed as a placebo-controlled study to test safety and efficacy, with an planned enrollment of about 100 healthy patients with PDD. The trial will be conducted at the Canadian Centre for Psychedelic Science and the University of Toronto, with funding from the …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
